ALNY vs. RDY: Alnylam Pharmaceuticals vs. Dr. Reddy's Laboratories Stock Comparison

Company Profile

Alnylam Pharmaceuticals (ALNY) and Dr. Reddy's Laboratories (RDY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while RDY is classified in Pharmaceuticals.

Alnylam Pharmaceuticals (ALNY) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Dr. Reddy's Laboratories (RDY) at 7.34% also sits in the top quartile.

Alnylam Pharmaceuticals (ALNY) at 52.85% keeps the most of each sales dollar — above its industry’s net margin range — and Dr. Reddy's Laboratories (RDY) at 8.49% also retains a top-quartile share.

Alnylam Pharmaceuticals (ALNY) at 23.72% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Dr. Reddy's Laboratories (RDY) at 3.19% is closer to the peer norm — faster top-line expansion for ALNY.

Only one side can be read here: Dr. Reddy's Laboratories (RDY) reports EPS growth of -24.14%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Dr. Reddy's Laboratories (RDY) at 1.93 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RDY.

Dr. Reddy's Laboratories (RDY) at 0.19 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a yield of 55.06%, ranking against industry peers normally.

Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a payout of 22.72%, ranking against industry peers normally.

Dividend Metrics

Valuation

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Dr. Reddy's Laboratories (RDY) at 41.42 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Alnylam Pharmaceuticals (ALNY) at 4.17 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

Alnylam Pharmaceuticals (ALNY) at 5.79 sits near its industry’s typical P/B ratio, while Dr. Reddy's Laboratories (RDY) at 18.16 prices above its benchmark range — RDY looks rich relative to book.

Valuation Metrics